Earnings Call Insights: Acadia Healthcare Company, Inc. (ACHC) Q2 2025
Management View
- CEO Christopher Howal Hunter highlighted "solid top line growth with total revenue of $869.2 million, up 9.2% over the second quarter last year, while adjusted EBITDA was $201.8 million, a 7.5% increase over the same period a year ago." Hunter addressed the recently passed One Big Beautiful Bill Act, noting that "the provisions of the bill are manageable over the coming years particularly due to the carve-outs from work requirements and the extended time line for implementing changes to the supplemental payment provisions of the Medicaid program." For 2025, gross revenue from state Medicaid supplemental programs is expected to reach approximately $230 million, with more than half potentially affected by reductions starting in fiscal 2028 if proposed changes are enacted.
- Hunter reported the approval of a new Directed Payment Program in Tennessee, calling it "a meaningful step in the broader national movement to invest in behavioral health programs." Development activity included 101 beds added to existing facilities in Q2, totaling 479 beds year-to-date, and completion of three new joint venture facilities. Acadia now operates 174 comprehensive treatment centers (CTCs) across 33 states.
- Hunter noted that same-facility patient days increased by 1.8%, slightly below expectations, largely due to weaker Medicaid volumes in acute care. Commercial and Medicare volumes rose 9% and 8%, respectively. Hunter stated, "Medicaid volumes at our acute care hospitals were down slightly on a year-over-year basis in the second quarter, while commercial and Medicare volumes increased by 9% and 8%."
- The company reaffirmed its commitment to quality and technology investments, including "remote 24/7 patient monitoring devices" and "robust analytics through an integrated quality dashboard."
- Hunter announced CFO Heather Dixon's upcoming departure and named Tim Sides as interim CFO.
- CFO Heather Dixon reported, "We reported $869.2 million in revenue for the quarter, representing a 9.2% increase over the second quarter of last year. Adjusted EBITDA for the second quarter of 2025 was $201.8 million, reflecting an adjusted EBITDA margin of 23.2%." She highlighted a "favorable pretax benefit of $51.8 million" from the Tennessee Supplemental Payment Program and start-up losses of $14.2 million from newly opened facilities.
Outlook
- Dixon updated full-year adjusted EBITDA guidance to a range of $675 million to $700 million, citing lower expected volume growth and higher start-up costs, partially offset by increased supplemental payments. Same-facility volume growth is now expected in the 2% to 3% range, down from previous low to mid-single digits guidance. Start-up losses are anticipated at $60 million to $65 million, an increase of $10 million due to faster-than-expected bed openings. Net Medicaid supplementals are projected to increase by $30 million to $40 million year-over-year, with a recurring benefit of $40 million to $45 million from Tennessee.
- The company now expects to add 950 to 1,000 total beds in 2025, up from the previously expected range of 800 to 1,000 beds.
Financial Results
- The company reported $869.2 million in revenue and $201.8 million adjusted EBITDA for Q2 2025. Same-facility revenue grew 9.5% year-over-year, driven by a 7.5% increase in revenue per patient day and 1.8% growth in patient days. The second quarter results included start-up losses of $14.2 million and a pretax benefit of $51.8 million from the Tennessee Supplemental Payment Program. Cash and cash equivalents stood at $131.4 million, with $828 million available under the revolving credit facility.
Q&A
- Albert J. William Rice, UBS: Asked about Medicaid trends and volume softness. Hunter responded, "The primary driver of volume coming in below our expectations really was the weaker Medicaid volumes in our acute care business...we believe this reflects some of the evolving utilization patterns among managed Medicaid plans."
- Rice inquired about higher start-up losses. Dixon explained, "The $10 million in incremental start-up losses is reflective of an accelerated opening pace...experiencing those incremental start-up costs earlier in the year than what we would have previously anticipated."
- John Wilson Ransom, Raymond James: Questioned free cash flow outlook. Hunter stated, "We have the opportunity to take a pause on some of our expansion capital spending...we do think that there is opportunity to accelerate our path to becoming free cash flow positive as a result."
- Benjamin Whitman Mayo, Leerink Partners: Asked about underperforming facilities. Hunter said, "Our 2025 guidance assumed a roughly $20 million EBITDA headwind for the full year from this group of underperforming facilities," and Dixon added, "We are seeing that be about $3 million worse than what we had originally anticipated."
- Brian Gil Tanquilut, Jefferies: Inquired about wage trends and government investigations. Dixon replied, "We've seen a reduction in premium costs as well. It's now roughly around the 3.5% range for second quarter, and we see stability in that number." On legal costs, Hunter said, "We do currently anticipate a reduction and the costs associated with the investigation over the second half of the year."
- Multiple analysts asked about Medicaid payer behaviors, volume trends, guidance bridge, and capital allocation, with management emphasizing ongoing monitoring, quality investments, and portfolio optimization.
Sentiment Analysis
- Analysts' tone was slightly negative, focusing on Medicaid volume weakness, start-up losses, and underperforming facilities. Questions about free cash flow and government investigations reflected concern over cash generation and legal exposure.
- Management maintained a confident but cautious tone, particularly when discussing volume shortfalls and policy uncertainty. Hunter frequently expressed confidence in the company's strategic direction and quality initiatives while acknowledging local market challenges and policy headwinds. Dixon's responses to guidance and start-up losses remained measured and factual.
- Compared to the previous quarter, both analysts and management displayed increased caution regarding Medicaid volumes and the financial impact of policy changes.
Quarter-over-Quarter Comparison
- Guidance for same-facility volume growth was revised downward, and start-up loss expectations increased by $10 million, reflecting a faster pace of bed openings compared to Q1. Adjusted EBITDA guidance narrowed and now incorporates higher supplemental payments from Tennessee.
- Analysts shifted their focus from construction ramp and labor to Medicaid volume pressures and the financial impact of policy changes. Management's tone became more cautious, especially regarding local market variability and payer behavior.
- The prior quarter emphasized strong demand and stable rate trends, while the current quarter highlighted Medicaid headwinds and the need for portfolio optimization.
Risks and Concerns
- Management cited weaker Medicaid volumes in acute care, local market pressures on specific facilities, and evolving payer utilization patterns as ongoing risks. Hunter noted, "Weaker Medicaid volumes in our acute care business...appears these dynamics are having some impact on admissions trends."
- The start-up losses from accelerated bed expansion and the $3 million additional drag from underperforming facilities were called out as challenges.
- Analysts raised concerns about government investigation costs, capital allocation, and the potential long-term impact of the One Big Beautiful Bill Act.
Final Takeaway
Acadia Healthcare's Q2 2025 call highlighted revenue growth, continued bed expansion, and the impact of Medicaid policy developments. Management revised guidance to reflect lower volume growth and higher start-up costs, but anticipated increased supplemental payments. The transition to a new CFO, portfolio optimization efforts, and robust technology investments underscore the company’s response to local market and policy headwinds, while maintaining a focus on quality care and strategic growth.
Read the full Earnings Call Transcript
More on Acadia Healthcare
- Acadia Healthcare Company, Inc. (ACHC) Q2 2025 Earnings Call Transcript
- Acadia Healthcare Company, Inc. (ACHC) Q1 2025 Earnings Call Transcript
- Acadia Healthcare Non-GAAP EPS of $0.83 beats by $0.12, revenue of $869.23M beats by $28.23M
- Acadia Healthcare Q2 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Acadia Healthcare
